APA (7th ed.) Citation

MG, L., L, S. G., K, P., G, H., DM, P., T, L., . . . A, J. (2021). Long-term safety and efficacy of a fixed-combination halobetasol propionate 0.01%/tazarotene 0.045% lotion in moderate-to-severe plaque psoriasis: Phase 3 open-label study. Journal of the European Academy of Dermatology and Venereology : JEADV, 35(5), 1152. https://doi.org/10.1111/jdv.17113

Chicago Style (17th ed.) Citation

MG, Lebwohl, Stein Gold L, Papp K, Han G, Pariser DM, Lin T, Harris S, and Jacobson A. "Long-term Safety and Efficacy of a Fixed-combination Halobetasol Propionate 0.01%/tazarotene 0.045% Lotion in Moderate-to-severe Plaque Psoriasis: Phase 3 Open-label Study." Journal of the European Academy of Dermatology and Venereology : JEADV 35, no. 5 (2021): 1152. https://doi.org/10.1111/jdv.17113.

MLA (9th ed.) Citation

MG, Lebwohl, et al. "Long-term Safety and Efficacy of a Fixed-combination Halobetasol Propionate 0.01%/tazarotene 0.045% Lotion in Moderate-to-severe Plaque Psoriasis: Phase 3 Open-label Study." Journal of the European Academy of Dermatology and Venereology : JEADV, vol. 35, no. 5, 2021, p. 1152, https://doi.org/10.1111/jdv.17113.